Pharmacodynamics of doxorubicin in human bladder tumors

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1275-1283

  Gan, Yuebo ^a   Wientjes, M Guillaume ^a,b,c   Badalament, Robert A ^b,c   Au, Jessie L S ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ARTICLE; BLADDER TUMOR; CANCER GRADING; CELL DEATH; CHEMOSENSITIVITY; DOSE RESPONSE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; LABELING INDEX; MULTIDRUG RESISTANCE; PREDICTION; PRIORITY JOURNAL; TARGET CELL;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BROMODEOXYURIDINE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0029737679     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Herr, H. W. Intravesical therapy, a critical review, Urol. Clin. North Am., 14: 399-404, 1987.
2. Schmittgen, T. D., Au, J. L-S., Wientjes, M. G., and Badalament, R. A. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res., 51: 3849-3856, 1991.
3. Wientjes, M. G., Badalament, R A., Wang, R. C., Hassan, F., and Au, J. L-S, Penetration of mitomycin C in human bladder. Cancer Res., 53: 3314-3320, 1993.
4. Wientjes, M. G., Badalament, R. A., and Au. J. L-S. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. Pharmacol., 32: 255-262, 1993.
5. Au, J. L-S. Integrated pharmacokinetic and pharmacodynamic studies to improve intravesical treatment of bladder cancer. Cancer Bull. (Houst.), 46: 48-57, 1994.
6. Chai, M. F., Wientjes, M. G., Badalament, R. A., Burgers, J. K., and Au, J. L-S. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J. Urol., 152: 374-378, 1994.
7. Schmittgen, T. D., Weaver, J. M., Badalament, R. A., Wientjes, M. G., Klein, E. A., Young, D. C., and Au, J. L-S. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J. Urol., 152: 1632-1636, 1994.
8. Naito, S., Sakamoto, N., Kotoh, S., Goto, K., Matsumoto, T., and Kumazawa, J. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur. Urol., 22: 158-162, 1992.
9. Seemann, O., Muscheck, M., Siegsmund, M., Pilch, H., Nebe, C. T., Rassweiler, J., and Aiken, P. Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21. Urol. Res., 22: 353-360, 1995.
10. Shinohara, N., Liebert, M., Wedemeyer, G., Chang, J. H., and Grossman, H. B. Evaluation of multiple drug resistance in human bladder cancer cell lines. J. Urol., 750: 505-509, 1993.
11. Kimiya, K., Naito, S., Soejima, T, Sakamoto, N., Kotoh, S., Kumazawa, J., and Tsurue, T. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line KK47/ADM. J. Urol., 148: 441-445, 1992.
12. Park. J., Shinohara, N., Liebert, M., Noto L., Flint, A., and Grossman, H. B. P-glycoprotein expression in bladder cancer. J. Urol., 151: 43-46, 1994.
13. Lee, J. M., and Bernstein, A. Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metastasis Rev., 14: 149-161, 1995.
14. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
15. Hickman, J. A., Potten, C. S., Merritt, A. J., and Fisher, T. C. Apoptosis and cancer chemotherapy. Philos. Trans. R Soc. Lend. B. Biol. Sci., 345: 319-325, 1994.
16. Reed, J. C., Kitada, S., Takayama, S., and Miyashita, T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol., 5: 61-65, 1994
17. Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253-3259, 1994.
18. Weller, M., Malipiero, U., Aguzzi, A., Reed, J, C., and Fontana, A. Proto-oncogene bcl-2 gene transfer abrogates Fas/APO-1 antibodymediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest., 95: 2633-2643, 1995.
19. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. & Dev., 4: 71-79, 1994.
20. Vesico, R. A., Redfern, C. H., Nelson, R. J., Ugoretz, S., Stern, P. H., and Hoffman, R. M. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. USA, 84: 5029-5033, 1987.
21. Robbins, K. T , Connors, K. M., Storniolo, A. M., Hanchett, C., and Hoffman, R. M. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch. Otolaryngol. Head & Neck Surg., 120: 288-292, 1994.
22. Furukawa, T., Kubota, T., and Hoffman, R. M. The clinical applications of the histoculture drug response assay. Clin. Cancer Res., 1: 305-311, 1995.
23. Kubota, T., Sasano, N., Abe, O., Nakao, I., Kawamura, E., Saito, T., Endo, M., Kimura, K., Hiroshi, D , Sasano, H., Nagura, H., Ogawa, N., Hoffman, R. M., and the Chemosensitivity Study Group for the HLS-toculture Drug-Response Assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res., 1: 1537-1543, 1995.
24. Pauli, B. U., Alroy, J., and Weinstein, R. S. The ultrastructure and pathobiology of urinary bladder cancer. In: G. T. Bryan and S. M. Cohen (eds.), The Pathology of Bladder Cancer, Vol. 2, pp. 41-48. Boca Raton, FL: CRC Press, Inc., 1983.
25. Mostofi, F K , Sobin, L. H., and Torloni, H. Histological typing of urinary bladder tumors. In: International Histological Classification of Tumors, No. 10. Geneva, Switzerland: WHO, 1973.
26. Wientjes, M. G., Badalament, R. A., and Au, J. L-S. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother. Pharmacol., 37: 539-546, 1996.
27. Gan, Y., Wientjes, M. G., Schuller, D. E., and Au, J. L-S. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res., 56: 2086-2093, 1996.
28. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
29. Ludden, T. M., Beal, S. L., and Sheiner, L. B. Comparison of the Akaike Information Criterion, the Schwartz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm., 22: 431-445, 1994.
30. Dalton, J. T., Wientjes, M. G., Badalament, R. A., Drago. J. R., and Au, J. L-S. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res., 51: 5144-5152, 1991.
31. Myers, C. E., Jr., and Chabner, B. A. Anthracyclines. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy: Principles and Practices, pp. 356-381. Philadelphia: J. B. Lippincott Co., 1990.
32. Dalbagni, G., Presti, J. C., Jr., Reuter, V. E., Zhang, Z. F., Sarkis, A. S., Fair, W. R., and Cordon-Cardo, C. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn. Mol. Pathol., 2: 4-13, 1993.
33. Soini, Y., Turpeenniemi-Hujanen, T., Kamel, D., Autio-Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Paakko, P., and Vahakangas, K. p53 immunohistochemistry in transition cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer, 68: 1029-1035, 1993.
34. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T., and Terada, M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393-1398, 1992.
35. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer. Inst., 85: 53-59, 1993.
36. Yoshimura, I., Kudoh, J., Saito, S., Tazaki, H., and Shimizu, N. p53 gene mutation in recurrent superficial bladder cancer. J. Urol., 153: 1711-1715, 1995.
37. Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama. E., Kameya, T., and Koshiba, K. p53 mutations and prognosis in bladder tumors. J. Urol., 153: 1097-1104, 1995.
38. Lipponen, P. K. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
39. Furihara, M., Inoue, K., Ohtsuki, Y., Hashimoto, H., Terao, N., and Fujita, Y High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res., 53: 4823-4827, 1993.
40. Kwok, T. T., Mok, C. H., and Menton-Brennan, L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res., 54: 2834-2836, 1994.
41. Vikhanskaya, F., D'Incalci, M., and Broggini, M. Effects of DNA damaging agents on gene expression in two human cancer cell lines. Cell. Mol. Biol., 39: 855-862, 1992.
42. Daidone, M G., Silvestrim, R., Luisi, A., Mastore, M., Benini, E., Veneroni, S., Brambilla, C., Ferrari, L., Greco, M., Andreola, S., and Veronesi, U. Changes in biological markers after chemotherapy for breast cancers. Int. J. Cancer, 61: 301-305, 1995.
43. Moriyama, M., Sugawara, I., Hamada, H., Tsuruo, T., Kato, T., Sato, K., Hikage, T., Watanuki, T., and Mori, S. Elevated expression of P-glucoprotein in kidney and urinary bladder cancers. Tohoku J. Exp. Med., 164: 191-201, 1991.
44. Benson, M. C., Giella, J., Whang, I. S., Buttyan, R., Hensle, T. W., Karp, F., and Olson, C. A. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder. implications and applications. J. Urol., 146: 982-986, 1991.
45. Petrylak, D. P., Scher, H. I., Reuter, V., O'Brien, J. P., and Cordon-Cardo, C. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann. Oncol., 5: 835-840, 1994.